Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.

Giorgio, Anna et al.·Journal of clinical medicine·2025·
RPEP-111092025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.
Published In:
Journal of clinical medicine, 14(21) (2025)
Database ID:
RPEP-11109

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-11109·https://rethinkpeptides.com/research/RPEP-11109

APA

Giorgio, Anna; Varani, Michela; Lauri, Chiara; Bentivoglio, Valeria; Nayak, Pallavi. (2025). Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.. Journal of clinical medicine, 14(21). https://doi.org/10.3390/jcm14217811

MLA

Giorgio, Anna, et al. "Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14217811

RethinkPeptides

RethinkPeptides Research Database. "Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Ag..." RPEP-11109. Retrieved from https://rethinkpeptides.com/research/giorgio-2025-radiolabeled-lhrh-and-fsh

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.